RxSight, Inc.

Equities

RXST

US78349D1072

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-21 pm EDT			5-day change	1st Jan Change
62.36 ^USD	-0.45%		+3.57%	+54.66%

May. 21	Rxsight Insider Bought Shares Worth $305,457, According to a Recent SEC Filing	MT
May. 15	Transcript : RxSight, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 through May-16-2024

RxSight, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023

May 09, 2023 at 04:18 pm EDT

RxSight, Inc. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported sales was USD 17.49 million compared to USD 8.94 million a year ago. Net loss was USD 13.21 million compared to USD 17.6 million a year ago.

Basic loss per share from continuing operations was USD 0.42 compared to USD 0.64 a year ago.

Latest news about RxSight, Inc.

Rxsight Insider Bought Shares Worth $305,457, According to a Recent SEC Filing	May. 21	MT
Transcript : RxSight, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 through May-16-2024	May. 15
RxSight Raises $115 Million From Public Offering of Shares	May. 13	MT
Wells Fargo Adjusts RxSight Price Target to $68 From $61, Maintains Overweight Rating	May. 07	MT
Oppenheimer Adjusts RxSight Price Target to $72 From $61, Maintains Outperform Rating	May. 07	MT
Needham Adjusts Price Target on RxSight to $75 From $64, Maintains Buy Rating	May. 07	MT
BTIG Adjusts Price Target on RxSight to $72 From $61, Maintains Buy Rating	May. 07	MT
RxSight Q1 Adjusted Loss Narrows, Revenue Rises	May. 07	MT
Rxsight Insider Sold Shares Worth $2,405,872, According to a Recent SEC Filing	May. 06	MT
Transcript : RxSight, Inc., Q1 2024 Earnings Call, May 06, 2024	May. 06
Earnings Flash (RXST) RXSIGHT Posts Q1 Revenue $29.5M, vs. Street Est of $27.6M	May. 06	MT
RxSight, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 06	CI
RxSight, Inc. Increases Earnings Guidance for the Full Year 2024	May. 06	CI
Rxsight Insider Sold Shares Worth $526,913, According to a Recent SEC Filing	May. 02	MT
RxSight Launches New Light Adjustable Lens Product	Apr. 04	MT
RxSight, Inc. Announces Commercial Launch of its Newest Light Adjustable Lens??, the LAL+??, and Features Multiple Doctor Presentations at the Upcoming ASCRS Annual Meeting	Apr. 04	CI
Rxsight Insider Sold Shares Worth $997,946, According to a Recent SEC Filing	Apr. 02	MT
Needham Raises Price Target on RxSight to $64 From $53, Maintains Buy Rating	Feb. 29	MT
Oppenheimer Adjusts RxSight Price Target to $61 From $54, Maintains Outperform Rating	Feb. 29	MT
RxSight's Q4 Adjusted Loss Narrows, Sales Increase; Reiterates 2024 Revenue Guidance	Feb. 29	MT
Transcript : RxSight, Inc., Q4 2023 Earnings Call, Feb 28, 2024	Feb. 28
Earnings Flash (RXST) RXSIGHT Reports Q4 Revenue $28.6M, vs. Street Est of $27.9M	Feb. 28	MT
Rxsight, Inc. Reiterates Earnings Guidance for the Full Year 2024	Feb. 28	CI
RxSight, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 28	CI
RxSight, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 28	CI

Chart RxSight, Inc.

Duration

Period

More charts

Company Profile

RxSight, Inc. is a commercial-stage medical technology company, which is engaged in improving the vision of patients following cataract surgery. The Companyâs RxSight Light Adjustable Lens system (RxSight system) is a cataract technology that enables doctors to customize and optimize visual acuity for patients after surgery. The RxSight system includes the RxSight Light Adjustable Lens (LAL), the RxSight Light Delivery Device (LDD), and various accessories. Its LAL is an intraocular lens (IOL) made of photosensitive material that changes shape in response to specific patterns of ultraviolet (UV) light generated by its LDD. It designed its RxSight system to address the shortcomings of competitive IOL technologies and provide a solution that doctors can trust to improve visual outcomes. Its RxSight system helps the surgeon perform a standard cataract procedure to implant the LAL and then uses the LDD to modify the lens with the visual correction needed for the patientâs vision outcomes.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-06-06 - Annual General Meeting

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for RxSight, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

62.36 USD

Average target price

72.75 USD

Spread / Average Target

+16.66%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
RXSIGHT, INC.	+54.66%	2.43B
ABBOTT LABORATORIES	-6.46%	179B
MEDTRONIC PLC	+3.39%	113B
BECTON, DICKINSON AND COMPANY	-3.68%	67.88B
DEXCOM, INC.	+5.44%	52.03B
CENCORA, INC.	+5.70%	43.3B
HOYA CORPORATION	+4.60%	41.79B
METTLER-TOLEDO INTERNATIONAL, INC.	+25.42%	32.49B
TERUMO CORPORATION	+14.13%	25.65B
WEST PHARMACEUTICAL SERVICES, INC.	-4.29%	24.55B

Other Medical Equipment, Supplies & Distribution